Funder: Breakthrough T1D
Due Dates: October 29, 2025 (LOI) | January 13, 2026 (Full proposal)
Funding Amounts: Up to $3,000,000 total for up to 3 years per award; smaller budgets considered.
Summary: Supports clinical trials to advance therapies targeting cardiovascular disease in people with type 1 diabetes, aiming to improve prevention, treatment, and management of CVD in this population.
Key Information: LOI approval is required before submitting a full proposal.